Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the phase I/II clinical trial drug S-1360

Myriam Witvrouw; Valery Fikkert; Christophe Pannecouque; Barbara Van Remoortel; De Clercq Erik; Zeger Debyser

Related publications

Article2004

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360

Valery Fikkert, Anneleen Hombrouck, Barbara Van Remoortel, Marc De Maeyer, Christophe Pannecouque, De Clercq Erik, Zeger Debyser, Myriam Witvrouw

Article2004

Multiple Mutations in Human Immunodeficiency Virus-1 Integrase Confer Resistance to the Pyranodipyrimidine V-165

Myriam Witvrouw, Anke Hantson, Anneleen Hombrouck, Katrien Busschots, Tetz, Christophe Pannecouque, De Clercq Erik, Bénédicte Van Maele, Zeger Debyser

Article2005

The V165I and T206S/S230N mutations in Human Immunodeficiency Virus-1 integrase confer resistance to the pyranodipyrimidine V-165 and reduce replication capacity

Myriam Witvrouw, Anke Hantson, Anneleen Hombrouck, Jo Vercammen, Tetz, Christophe Pannecouque, Yves Engelborghs, De Clercq Erik, Zeger Debyser

Article2003

Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations

Valery Fikkert, Bénédicte Van Maele, Jo Vercammen, Anke Hantson, Barbara Van Remoortel, Martine Michiels, Cristina Gurnari, Christophe Pannecouque, Marc De Maeyer, Yves Engelborghs, De Clercq Erik, Zeger Debyser, Myriam Witvrouw

Article1994

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720

Jan Balzarini, Anna Karlsson, C Meichsner, Arno Paessens, G Riess, De Clercq Erik, J P Kleim